These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22966986)

  • 1. Effects of the TRPV1 antagonist ABT-102 on body temperature in healthy volunteers: pharmacokinetic/ pharmacodynamic analysis of three phase 1 trials.
    Othman AA; Nothaft W; Awni WM; Dutta S
    Br J Clin Pharmacol; 2013 Apr; 75(4):1029-40. PubMed ID: 22966986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of the TRPV1 antagonist ABT-102 in healthy human volunteers: population analysis of data from 3 phase 1 trials.
    Othman AA; Nothaft W; Awni WM; Dutta S
    J Clin Pharmacol; 2012 Jul; 52(7):1028-41. PubMed ID: 21566201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial.
    Rowbotham MC; Nothaft W; Duan RW; Wang Y; Faltynek C; McGaraughty S; Chu KL; Svensson P
    Pain; 2011 May; 152(5):1192-1200. PubMed ID: 21377273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia.
    Honore P; Chandran P; Hernandez G; Gauvin DM; Mikusa JP; Zhong C; Joshi SK; Ghilardi JR; Sevcik MA; Fryer RM; Segreti JA; Banfor PN; Marsh K; Neelands T; Bayburt E; Daanen JF; Gomtsyan A; Lee CH; Kort ME; Reilly RM; Surowy CS; Kym PR; Mantyh PW; Sullivan JP; Jarvis MF; Faltynek CR
    Pain; 2009 Mar; 142(1-2):27-35. PubMed ID: 19135797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An oral TRPV1 antagonist attenuates laser radiant-heat-evoked potentials and pain ratings from UV(B)-inflamed and normal skin.
    Schaffler K; Reeh P; Duan WR; Best AE; Othman AA; Faltynek CR; Locke C; Nothaft W
    Br J Clin Pharmacol; 2013 Feb; 75(2):404-14. PubMed ID: 22775239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management.
    Gomtsyan A; Bayburt EK; Schmidt RG; Surowy CS; Honore P; Marsh KC; Hannick SM; McDonald HA; Wetter JM; Sullivan JP; Jarvis MF; Faltynek CR; Lee CH
    J Med Chem; 2008 Feb; 51(3):392-5. PubMed ID: 18183945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of TRPV1 antagonist ABT-116.
    Brown BS; Keddy R; Perner RJ; DiDomenico S; Koenig JR; Jinkerson TK; Hannick SM; McDonald HA; Bianchi BR; Honore P; Puttfarcken PS; Moreland RB; Marsh KC; Faltynek CR; Lee CH
    Bioorg Med Chem Lett; 2010 Jun; 20(11):3291-4. PubMed ID: 20457518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analgesic potential of TRPV1 antagonists.
    Kym PR; Kort ME; Hutchins CW
    Biochem Pharmacol; 2009 Aug; 78(3):211-6. PubMed ID: 19481638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo.
    Surowy CS; Neelands TR; Bianchi BR; McGaraughty S; El Kouhen R; Han P; Chu KL; McDonald HA; Vos M; Niforatos W; Bayburt EK; Gomtsyan A; Lee CH; Honore P; Sullivan JP; Jarvis MF; Faltynek CR
    J Pharmacol Exp Ther; 2008 Sep; 326(3):879-88. PubMed ID: 18515644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.
    Voight EA; Gomtsyan AR; Daanen JF; Perner RJ; Schmidt RG; Bayburt EK; DiDomenico S; McDonald HA; Puttfarcken PS; Chen J; Neelands TR; Bianchi BR; Han P; Reilly RM; Franklin PH; Segreti JA; Nelson RA; Su Z; King AJ; Polakowski JS; Baker SJ; Gauvin DM; Lewis LR; Mikusa JP; Joshi SK; Faltynek CR; Kym PR; Kort ME
    J Med Chem; 2014 Sep; 57(17):7412-24. PubMed ID: 25100568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single- and multiple dose pharmacokinetics and multiple dose pharmacodynamics of oral ABT-116 (a TRPV1 antagonist) in dogs.
    Niyom S; Mama KR; Gustafson DL; Rezende ML
    J Vet Pharmacol Ther; 2015 Aug; 38(4):336-43. PubMed ID: 25376244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 antagonists.
    Perner RJ; DiDomenico S; Koenig JR; Gomtsyan A; Bayburt EK; Schmidt RG; Drizin I; Zheng GZ; Turner SC; Jinkerson T; Brown BS; Keddy RG; Lukin K; McDonald HA; Honore P; Mikusa J; Marsh KC; Wetter JM; George KS; Jarvis MF; Faltynek CR; Lee CH
    J Med Chem; 2007 Jul; 50(15):3651-60. PubMed ID: 17583335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the transient receptor potential vanilloid 1 antagonist A-425619 on body temperature and thermoregulation in the rat.
    Mills C; McMackin M; Jaffe R; Yu J; Zininberg E; Slee D; Gogas K; Bradbury M
    Neuroscience; 2008 Sep; 156(1):165-74. PubMed ID: 18706981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans.
    Chizh BA; O'Donnell MB; Napolitano A; Wang J; Brooke AC; Aylott MC; Bullman JN; Gray EJ; Lai RY; Williams PM; Appleby JM
    Pain; 2007 Nov; 132(1-2):132-41. PubMed ID: 17659837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects.
    Round P; Priestley A; Robinson J
    Br J Clin Pharmacol; 2011 Dec; 72(6):921-31. PubMed ID: 21676011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multiple-dose double-blind randomized study to evaluate the safety, pharmacokinetics, pharmacodynamics and analgesic efficacy of the TRPV1 antagonist JNJ-39439335 (mavatrep).
    Manitpisitkul P; Flores CM; Moyer JA; Romano G; Shalayda K; Tatikola K; Hutchison JS; Mayorga AJ
    Scand J Pain; 2018 Apr; 18(2):151-164. PubMed ID: 29794306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transient Receptor Potential Vanilloid 1 Antagonists Prevent Anesthesia-induced Hypothermia and Decrease Postincisional Opioid Dose Requirements in Rodents.
    Garami A; Ibrahim M; Gilbraith K; Khanna R; Pakai E; Miko A; Pinter E; Romanovsky AA; Porreca F; Patwardhan AM
    Anesthesiology; 2017 Nov; 127(5):813-823. PubMed ID: 28806222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Learnings from a Double-Blind, Randomized, Placebo-Controlled, Sequential Group First-in-Human Study of the TRPV1 Antagonist, JNJ-38893777, in Healthy Men.
    Manitpisitkul P; Mayorga A; Shalayda K; De Meulder M; Romano G; Jun C; Moyer JA
    Clin Drug Investig; 2015 Jun; 35(6):353-63. PubMed ID: 25894894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The circadian body temperature rhythm in the elderly: effect of single daily melatonin dosing.
    Gubin DG; Gubin GD; Waterhouse J; Weinert D
    Chronobiol Int; 2006; 23(3):639-58. PubMed ID: 16753947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRPV1 antagonists: clinical setbacks and prospects for future development.
    Kort ME; Kym PR
    Prog Med Chem; 2012; 51():57-70. PubMed ID: 22520471
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.